Press Releases

Harvard Apparatus Regenerative Technology CEO David Green Interviewed on Fox Business News’ Varney & Company on May 13
Green Explains How HART-Trachea Scaffold and Bioreactor Are Used To Create Replacement Tracheas for Transplant

HOLLISTON, Mass.--(BUSINESS WIRE)--David Green, CEO of Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, was interviewed by anchor Stuart Varney on the Fox Business News program Varney & Company on May 13.

In the segment, titled “New advances in medical tech: Synthetic trachea transplants,” Mr. Green showed the HART-Trachea bioreactor and scaffold, and described the electrospinning technique used to create the fibers comprising the scaffold. He discussed how the scaffold is combined with a patient’s stem cells to grow a replacement trachea for transplant, and noted that eight patients have undergone the procedure to date.

To view the interview in its entirety, please visit the following link: - /v/3563467601001

The video at the link above is provided for informational purposes only. Harvard Apparatus Regenerative Technology, Inc. is not responsible for the content of the linked video.

About Harvard Apparatus Regenerative Technology

Harvard Apparatus Regenerative Technology makes regenerated organs for transplant. Our first product, the HART-Trachea, is intended to replace or repair a trachea that has been severely damaged by either trachea cancer or physical trauma. Our trachea scaffold technology has been used in five human trachea transplants to date approved under compassionate use exemptions, but none of our products are yet approved by a government regulatory authority for marketing. On November 1, 2013, HART was spun-off from Harvard Bioscience. The trademark “Harvard Apparatus” is used under a sublicense agreement with Harvard Bioscience, who has licensed the right to use such trademark from Harvard University.

Forward-Looking Statements

Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements in this press release include, but are not limited to, statements relating to any continued benefits of our spin-off from Harvard Bioscience, anticipated future earnings or other financial measures, success with respect to any clinical trials and other regulatory approval efforts, including with respect to the FDA, commercialization efforts and marketing approvals of HART’s products as well as the success thereof, including our HART-Trachea product, and the continued availability of a market for the HART securities. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, our ability to obtain and maintain regulatory approval for the bioreactors, scaffolds and other devices and product candidates we pursue; the success of our clinical trials and device; our inability to operate effectively as a stand-alone, publicly traded company; plus other factors described under the heading “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013 or described in our other public filings. Our results may also be affected by factors of which we are not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Harvard Apparatus Regenerative Technology expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.


Harvard Apparatus Regenerative Technology
David Green
President and CEO
Tom McNaughton
Investor Relations:
Dian Griesel Int’l.
Cheryl Schneider, 212-825-3210
Public Relations:
Dian Griesel Int’l.
Susan Forman or Laura Radocaj, 212-825-3210